Drug intelligence / Profile preview

mAb7

Development stage: Preclinical
Lead developer: Stainwei Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

mAb7 is a preclinical-stage monoclonal antibody being developed by Stainwei Biotechnology (Suzhou Stainwei Biotech Inc.) for the treatment of oncology indications. The antibody is designed to target TLF, a biological target associated with tumor progression. Currently, mAb7 is undergoing preclinical studies to evaluate its therapeutic potential and safety profile as a targeted therapy for solid tumors. It is part of Stainwei's broader pipeline of monoclonal antibodies targeting various inflammatory and oncogenic pathways.

Beyond the preview

Go deeper on mAb7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb7.

Explore the full profile